^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vyxeos (cytarabine/daunorubicin liposomal formulation) (DNA synthesis inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis
Published date:
11/04/2021
Excerpt:
Sixty-six pts with confirmed s-AML received CPX-351 therapy...Of the 19 pts with TP53 mutation eligible for response assessment, 6 pts (31.5%) achieved CR, 2 pts (10.5%) had a PR…
DOI:
10.1182/blood-2021-153791
Source:
Title:
1911 Distinct Clinical and Genetic Factors Predict Early Versus Late Mortality in AML Patients Undergoing Induction Chemotherapy
Published date:
11/04/2020
Excerpt:
We identified 290 consecutive adult patients treated with standard induction chemotherapy (“7+3” with cytarabine and an anthracycline, or CPX-351) for newly diagnosed AML...the presence of TP53 mutation, U2AF1 mutation, or 11q23 rearrangement were independently associated with inferior OS after day 60, whereas the presence of CBF rearrangement was independently associated with superior OS after day 60...
Source:
Title:
2845 Treatment with CPX-351 Induces Deep Responses and TP53 Mutation Clearance in Patients with t-AML and AML MRC, Including Younger Patients and Those with Pre-Existing MPNs: A Real-World Experience
Published date:
11/04/2020
Excerpt:
Among those who had TP53 mutation at baseline, 14 were available for response assessment after induction. The ORR in this subgroup was 57% (8/14) and all but 3 (63%) were MRD negative by NGS....Remission rates and MRD clearance was high among TP53 mutants.
